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Abstract
Background: Epidemiologic studies have highlighted the association of environmental factors with the development
and progression of autoimmune and chronic inflammatory diseases. Among the environmental factors, smoking has
been associated with increased susceptibility and poor prognosis in rheumatoid arthritis (RA). However, the immune
and molecular mechanism of smoking-induced arthritis aggravation remains unclear. The transcription factor aryl
hydrocarbon receptor (AHR) regulates the generation of Th17 cells, CD4 T cells linked the development of
autoimmune diseases. AHR is activated by organic compounds including polycyclic aromatic hydrocarbons (PAHs),
which are environmental pollutants that are also present in cigarette smoke. In this study, we investigated the role of
AHR activation in the aggravation of experiment arthritis induced by exposure to cigarette smoke.
Methods: Mice were exposed to cigarette smoke during the developmental phase of antigen-induced arthritis and
collagen-induced arthritis to evaluate the effects of smoking on disease development. Aggravation of articular
inflammation was assessed by measuring neutrophil migration to the joints, increase in articular hyperalgesia and
changes in the frequencies of Th17 cells. In vitro studies were performed to evaluate the direct effects of cigarette
smoke and PAH on Th17 differentiation. We also used mice genetically deficient for AHR (Ahr KO) and IL-17Ra (Il17ra
KO) to determine the in vivo mechanism of smoking-induced arthritis aggravation.
Results: We found that smoking induces arthritis aggravation and increase in the frequencies of Th17 cells. The
absence of IL-17 signaling (Il17ra KO) conferred protection to smoking-induced arthritis aggravation. Moreover, in vitro
experiments showed that cigarette smoke can directly increase Th17 differentiation of T cells by inducing AHR
activation. Indeed, Ahr KO mice were protected from cigarette smoke-induced arthritis aggravation and did not display
increase in TH17 frequencies, suggesting that AHR activation is an important mechanism for cigarette smoke effects on
arthritis. Finally, we demonstrate that PAHs are also able to induce arthritis aggravation.
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Conclusions: Our data demonstrate that the disease-exacerbating effects of cigarette smoking are AHR
dependent and environmental pollutants with AHR agonist activity can induce arthritis aggravation by directly
enhancing Th17 cell development.
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Background
Smoking is the major known environmental risk factor
associated with the development of rheumatoid arthritis
(RA) [1, 2]. Epidemiologic studies show that current and
previous smoking is correlated not only with increased
risk to RA development, but also to increased disease se-
verity and reduced responsiveness to therapy [3]. Heavy
smokers have twice the chance of developing RA than
non-smokers [4] and an increased risk for radiographic
progression [5]. Several molecular mechanisms for the
increase in arthritis severity have been proposed, such as
the increase in oxidative stress [6, 7], induction of en-
zymes that increase protein citrullination [8–11], and
nicotine activation of α7-nicotinic acetylcholine recep-
tors in neutrophils [12]. However, little is known about
the molecular mechanism by which smoking affects the
adaptive immune response on arthritis. Indeed, des-
pite its pro-inflammatory effects on neutrophils [12],
nicotine has an immunosuppressive effect on the
immune system, suggesting that other components of
cigarette smoke might be related to modulation of
disease severity [13].
Among the cells for adaptive immunity, a population of
interleukin 17 (IL-17)-producing CD4+ T cells (Th17) has
been implicated as a key player in RA development and
progression [14, 15]. Differentiation of Th17 cells follows
a complex transcriptional regulatory network dependent
on the nuclear receptor RORγt and its collaboration with
other transcription factors [16]. Recent reports suggest
that the transcription factor aryl hydrocarbon receptor
(AHR) plays an important role in the regulation of Th17
cells development. Activation of AHR increases Th17
differentiation in vitro and Ahr genetic-deficient mice de-
velop less severe collagen-induced arthritis via modulation
of Th17 [17–19]. AHR, a member of the basic helix-loop-
helix Per-Arnt-Sim (bHLH-PAS) superfamily, is a ligand-
dependent transcription factor also known as ‘pollutant
receptor’. This receptor is activated by a variety of organic
compounds including polycyclic aromatic hydrocarbons
(PAH) [20]. These are persistent organic environmental
pollutants, which are present in cigarette smoke [21, 22].
We hypothesized that AHR activation by cigarette
smoke components could be responsible for the
aggravation of arthritis.
To understand how smoking modulates the immune
response and disease aggravation, we developed a murine
model of cigarette smoke exposure during antigen-
induced articular disease development. Using this model,
we identified that smoking-induced arthritis aggravation is
dependent on AHR activation in T cells, Th17 expansion,
and interleukin 17 receptor A (IL-17RA) signaling, show-
ing a strong link between this pollutant receptor and arth-
ritis progression. Our results suggest that AHR activation
in Th17 cells might be a convergent mechanism by which




The following materials were used: AHR agonist FICZ
(6-formylindolo[3,2-b]carbazole, BIOMOL, Plymouth
Meeting, PA, USA,); AHR antagonist CH223191 (1-Me-
thyl-N-[2-methyl-4-[2-(2-methylphenyl)diazenyl]phenyl-
1H-pyrazole-5-carboxamide, Tocris Bioscience, Ellisville,
MO, USA); anti-CD3 and anti-CD28 (eBioscience, San
Diego, CA, USA) benzo[b]fluoranthen, phorbol-12-
myristate-13-acetate (PMA), ionomycin, methylated
bovine serum albumin (mBSA), complete Freund’s adju-
vant (CFA)with 1 mg/ml of Mycobacterium tuberculosis
and RPMI 1640 medium (all from Sigma-Aldrich, St.
Louis, MO, USA), α-IL-17a (eBioscience, anti-mouse IL-
17A functional grade purified, Clone: eBioMM17F3).
Mice
C57BL/6 wild-type (WT), DBA1/J and Il17 receptor
genetic-deficient mice on the C57BL/6 background
(Il17ra−/−) [23] were bred in a specific pathogen-free
animal facility at the School of Medicine of Ribeirao
Preto, University of São Paulo. Ahr−/− mice [24] on the
C57BL/6 background and their corresponding WT mice
were bred in a specific pathogen-free animal facility at
the Immunologie et Neurogenetique Experimentales et
Moleculaires, Orleans, France (Centre National de la
Recherche Scientifique, Orleans, France). Naïve male
mice (6- to 12-weeks old) were maintained in sterile,
isolated, ventilated cages with controlled temperature,
light conditions and ad libitum access to food and water.
All the genetic-deficient mice (Il17ra−/− and Ahr−/−)
displayed overall good health conditions and optimal
breeding. Animal husbandry and procedures were in
accordance with the guidelines of the Animal Ethics
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Committee of the School of Medicine of Ribeirao Preto,
University of São Paulo (number 038/2009).
Induction of experimental arthritis
Antigen-induced arthritis (AIA)
Mice were anesthetized with 2% isoflurane before
immunization and challenge. Mice were injected sub-
cutaneously (s.c.) on day 0 with 500 μg of mBSA in 0.
2 ml of an emulsion containing 0.1 ml saline and 0.1 ml
CFA, and boosted on day 7 and 14 with the same prep-
aration in incomplete Freund’s adjuvant (IFA). Sham-
immunized mice were given similar injections without
mBSA. On day 21 after the first immunization, mice
were challenged by intra-articular (i.a.) injection of
mBSA (10 μg in 10 μl of PBS) into the right knee joint
using a sterile 33-gauge syringe. Control mice were
injected with 10 μl of PBS alone. Mechanical articular
hyperalgesia and neutrophil infiltration were evaluated
7 h after challenge on day 21 after first immunization.
For evaluation of Th17 cell frequencies draining lymph
nodes (DLNs) were collected 18 days after first
immunization and analyzed by flow cytometry. For
histologic analysis of the knee joints, mice were chal-
lenged 7 days after first mBSA injection and euthanized
7 days later to excise the femur-tibial joints. Mice were
treated with FICZ (90 μg/kg, i.p.) or vehicle [dimethyl
sulfoxide (DMSO) 1% in PBS] twice (on days 12 and 17
after first immunization). We selected the in vivo dose
of FICZ based in a pilot dose-response curve
experiment (10, 30 and 90μg/kg) with showed that
90μg/kg induces the higher increase disease aggrava-
tion (data not shown).
Collagen-induced arthritis (CIA) [25]
Male DBA/1 J mice (10 weeks old) were injected intra-
dermally (i.d.) on day 0 at the base of the tail with
200 μg of bovine type II collagen (CII, a gift of Dr. David
D. Brand, University of Tennessee Health Science Cen-
ter) emulsified in CFA. Mice were boosted i.d. with CII
(200 μg emulsified in IFA) on day 21 and monitored
daily for signs of arthritis. Scores were assigned based on
erythema, swelling, or ankylosis present in each paw on
a scale of 0 to 3, giving a maximum score of 12 per
mouse. Mice were treated with FICZ (90 μg/kg, i.p.) or
vehicle (DMSO 1% in PBS) twice (on days 12 and 17
after first immunization). All mice were euthanized on
day 31 for evaluation of neutrophil infiltration in the
femur-tibial joints [by myeloperoxidase (MPO) activity]
and measurement of cytokines in the paws.
Pharmacologic and immunobiologic protocols
For AHR blockage experiments mice were treated with
an AHR antagonist, CH223191 (2.5 mg/kg, i.p.), every
day from 11 to 19 day after first immunization. For
neutralization of IL-17 activity during AIA development,
mice were treated (i.p.) with an anti-mouse/rat IL-17A
antibody, 5 mg/kg, daily, from 12 to 17 days after first
immunization.
Cigarette smoke exposure
Mice were exposed to smoke from commercial filter-
tipped cigarettes (Marlboro 100s, Phillip Morris, yielding
0.8 mg nicotine and 10 mg tar per cigarette) in a smok-
ing chamber modified from that of Sham [26]. Mice
were exposed to one, two or three cigarettes per day (4.
5 min per cigarette, five animals/chamber) twice on days
12 and 17 after first immunization. Smoke exposure was
carried out by intermittently forcing air (2.5 l/min)
through a burning cigarette. The intermittent cycles of
forcing clean air were performed to mimic human
smokers’ puff cycles and to prevent CO2-induced as-
phyxiation. Smoke cycles consisted of 15 s of active
cigarette smoke followed by 30 s of forced clean air
controlled by a two-way valve timer. For smoking > 1
cigarette per day, mice were rested for 3 h between
each cigarette.
Cigarette smoke-conditioned medium
The cigarette smoke-conditioned medium was prepared
as follows: smoke from two filtered cigarettes (Marlboro
100s, Phillip Morris) was bubbled through 10 ml serum-
free RPMI-1640 medium with a mechanical vacuum
pump. The extract was filtered through a 0.22 μm filter
(Millipore, Bedford, MA, USA) to remove bacteria and
particles and diluted to a final volume of 400 ml with
RPMI medium (five cigarettes/L). RPMI was chosen for
these experiments since it has a low intrinsic AhR activ-
ity, reducing the background for the assay of AhR activa-
tion and consequently increasing the noise-to-signal
ratio. Finally, CS-conditioned medium was incubated for
90 min at 37 °C, in room air. The pH of conditioned
medium was not different from that of untreated RPMI.
To standardize the concentration, AHR activity was
evaluated by a luciferase assay. In most experiments (ex-
cept described otherwise in the legends) CS-conditioned
medium was used at five cigarettes per liter.
Adoptive transfer of CD4+ T cells
CD4+ T cells (> 95% pure) were obtained from WT
C57BL/6 mice by negative selection (Miltenyi Biotec,
Bergisch Gladbach, Germany) and injected intravenously
(5 × 106 cells) into naïve Ahr−/− mice, which were
then immunized 1 day later by the AIA protocol
described above.
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Determination of articular hyperalgesia
Articular hyperalgesia of the femur-tibial joint was deter-
mined as previously described [27]. In a quiet room,
mice were placed in acrylic cages (12 × 10 × 17 cm high)
with a wire grid floor, 15–30 min before testing for
environmental adaptation. Stimulations were performed
only when animals were quiet, did not display explora-
tory movements or defecation, and were not resting on
their paws. An electronic pressure-meter consists of a
hand-held force transducer fitted with a polypropylene
tip (4.15 mm2) (IITC Inc., Life Science Instruments,
Columbia, MD, USA) was used. An increasing
perpendicular force was applied to the central area of
the plantar surface of the hind paw to induce flexion of
the femur-tibial joint followed by paw withdrawal. The
pressure of force applied when the paw was withdrawn
was recorded by the pressure meter. The test was
performed by investigators blinded to the treatment and
repeated until three consistent consecutive measure-
ments (variation < 1 g) were obtained. Mechanical
threshold is expressed in grams (g) and hyperalgesia is
equated to reduction of this threshold.
Assay for joint neutrophil infiltration
Seven hours after mBSA or PBS challenge AIA mice
were euthanized and articular cavities washed twice with
10 μl PBS containing 1 mM EDTA and then diluted to a
final volume of 50 μl with PBS/EDTA. Total number of
leukocytes was determined in a Neubauer chamber
diluted in Turk’s solution. Differential cell counts were
determined in cytocentrifuged Rosenfeld stained slices
(Shandon Cytospin 4, Thermo Fisher Scientific,
Waltham, MA, USA) with a light microscope. Results
are expressed as the number (mean ± SEM) of neutro-
phils per cavity.
Cytokine measurement in CIA mice
IL-17 cytokines were measured by ELISA from homoge-
nates of the mouse hind paws using paired antibodies
(R&D Systems, Minneapolis, MN, USA).
Determination of neutrophil accumulation in CIA
MPO activity was used as an index of neutrophil accu-
mulation in the mouse plantar tissues and was based on
a kinetic-colorimetric assay, as previously described [28].
mRNA expression in DLNs
Inguinal DLNs were harvested 7 days after first
immunization. Total RNA was extracted using TRIzol
(Invitrogen, Waltham, MA, USA) following manufac-
turer’s instructions. Total RNA was reverse-transcribed to
cDNA with oligo d(T)16 primers (Applied Biosystems,
Foster City, CA, USA). cDNA was used as template for
qPCR of genes of interest (SYBR green method) using
ViiA7 System (Applied Biosystems). mRNA expression
was analyzed using the following primers/probes (0.5
μM): Il17, F-CTCCAGAAGGCCCTCAGACTAC / R-
GGGTCTTCATTGCGGTGG; Gapdh, F-GGGTGTGAA
CCACGAGAAAT / R-CCTTCCACAATGCCAAAGTT;
Ahr, F-CAAATCAGAGACTGGCAGGA / R-AGAA
GACCAAGGCATCTGCT; Cyp1a1, F-GTTCTTGGAGC
TTCCCCGAT / R-CTGACACGAAGGCTGGAAGT.
Cell sorting and in vitro Th17 cell differentiation
CD4+ T cells were purified from spleen and lymph
nodes of C57BL/6 mice using anti-CD4 microbeads
(Miltenyi Biotech) and then stained in PBS with 2% FCS
for 15 min at room temperature with anti-CD4-FITC
and anti-CD62L-PercP (both Biolegend, San Diego, CA,
USA). The naive CD4+CD62Lhigh T cells were sorted
using the BD FACSAria II cell sorter. After sorting, cells
were activated for Th17 differentiation with anti-CD3
(2 μg/ml, plate-bound), anti-CD28 (2 μg/ml, soluble),
rhTGF-β1 (2.5 ng/ml, Miltenyi Biotec), and rmIL-6
(20 ng/ml, Miltenyi Biotec). Cells were cultured for 72 h
and analyzed by FACS.
Flow cytometry and intracellular cytokine staining
Cells from DLNs or in vitro differentiated T cells were
stimulated for 4 h with phorbol 12-myristate 13-aceate
(PMA) (50 ng/ml), ionomycin (500 ng/ml) and a protein
transport inhibitor containing monensin (BD Biosci-
ences, Franklin Lakes, NJ, USA) before detection by
staining with antibodies. Surface markers (anti-CD3 and
anti-CD4) were stained in PBS with 2% FCS for 10 min
at room temperature, then fixed in Cytoperm/Cytofix
(BD Biosciences), permeabilized with Perm/Wash Buffer
(BD Biosciences) and stained with allophycocyanin anti-
mouse interferon gamma (IFN-γ) and phycoerythrin
anti-IL-17A (both BD Bioscience). Cells were assayed by
FACS Canto or FACS Verse (both BD Biosciences)
and analyzed using Flow Jo software (Treestar, Ash-
land, OR, USA).
Luciferase assay to detect AHR agonist activity
Mammalian cell line (Hepa1–6) stably transfected with a
vector, pGL4.43 [luc2P/XRE/Hygro], containing a xeno-
biotic responsive elements (XRE) that drives transcription
of the luciferase reporter geneluc2P (Photinuspyralis) was
used. The vector contains a hygromycin resistance gene to
allow selection of stably transfected cell. For the luciferase
induction studies, cells were grown in 48-well plates (5 ×
105 cells/well) and incubated for 12 h with FICZ (300 nM)
, cigarette smoke-enriched medium (CSEM) or the AHR
ligands benzo[b]fluoranthen. Luciferase activity in cell
lysates was determined in a reaction with luciferin
using a microplate luminometer. Values are presented
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as the mean ± SD and are expressed as relative lumi-
nescence units.
Statistical analysis
Where appropriate (described in legends) data analysis
was performed using two-way analysis of variance
(ANOVA), unpaired two-tailed Student’s t test. Data are
expressed as means ± SEM and are representative of two
to three independent experiments. Means from different
treatments assessed in one time point were compared by
one-way ANOVA with Bonferroni’s correction. All statis-
tical analyses were performed with the GraphPad Prism
software 5.00 (GraphPad Software, San Diego, CA, USA).
P < 0.05 was considered statistically significant.
Results
Smoking induces aggravation of arthritis in an IL-17RA-
dependent manner
We developed a murine model of smoking exposure
during arthritis development to evaluate the mechanisms
by which environment pollutants might induce aggrava-
tion of autoimmune diseases. C57BL/6 mice were
exposed to cigarette smoke during the immunization
phase of AIA. Exposure to cigarette smoke induced a
dose-dependent increase in mechanical articular hyper-
algesia and neutrophil infiltration into the joints (Fig. 1a).
In the model of CIA, exposure to cigarette smoke also
exacerbated disease incidence, arthritis scores and neutro-
phil infiltration into the joints (Fig. 1b). We observed a
cigarette dose-dependent increase in the expression of
Il17 mRNA in the DLNs of mice during AIA development
(Fig. 1c). The frequencies of Th17 cells were also higher in
the DLNs of mice exposed to cigarette smoke than control
mice (Fig. 1d). Importantly, smoking-induced arthritis
aggravation, determined by neutrophil infiltration in the
joints and mechanical articular hyperalgesia in the AIA
model, was absent in mice genetically deficient of IL-
17RA (Il17ra−/−) (Fig. 1e). These results indicate that
cigarette smoking-induced aggravation of articular inflam-
mation is associated with an increase of Th17 frequencies
and dependent on IL-17RA.
Smoking-induced arthritis aggravation is dependent on
AhR activation
We then investigated the mechanism by which smoking
induces the increase in Th17 development. We observed
an increased expression of Ahr and Cyp1a1 (downstream
of Ahr activation) in the inguinal DLNs of mice during
AIA (Fig. 2a). Moreover, elevated levels of Cyp1a1
mRNA were clearly evident in the DLNs of mice under
AIA when exposed to cigarette smoke compared to
those mice exposed to air alone (Fig. 2b). Since AHR is a
key inducer of Th17 and Cyp1a1 is a downstream tran-
scription factor of Ahr these results indicate that smoke
exposure is inducing AHR activation during Th17 gener-
ation in vivo.
Consistent with this notion, smoking-induced arthritis
aggravation and increase in Th17 frequencies in AIA
was markedly inhibited when the mice were treated with
an AHR antagonist, CH223191 (Fig. 2c and d). Importantly,
while WT mice developed exacerbated hyperalgesia, in-
creased neutrophil infiltration and Th17 frequencies when
exposed to cigarette smoke during AIA, this aggravation
was completely absent in Ahr−/− mice (Fig. 2e and f). These
results therefore demonstrate that smoking-induced
arthritis aggravation is dependent on AHR activation and
elevation of Th17.
Cigarette smoke and polycyclic aromatic hydrocarbons
have direct effects on Th17 differentiation and arthritis
aggravation
Using a reporter cell line for AHR ligands (Hepa1–6
pGL4.43), we observed that CSEM induces a
concentration-dependent activation of AHR (Fig. 3a).
This CSEM was able to increase in vitro differentiation
of Th17 cells (Fig. 3b and c), which was abolished by the
AHR antagonist CH223191 (Fig. 3b and c). These data
suggest a strong link between direct influences of AHR
activation in Th17 cells.
We then investigated whether PAH present in
cigarette smoke could modulate Th17 differentiation and
exacerbate arthritis. As a PAH prototype we used
benzo[b]fluoranthen (BFA), which is found in high con-
centrations in cigarette smoke [29] and exhibits a potent
AHR agonist activity (Fig. 3d). BFA induced an increase
in Th17 differentiation in vitro to a similar level as that
induced by the AhR endogenous agonist, FICZ, or
CSEM (Fig. 3e and f). In vivo, BFA and FICZ also
induced arthritis aggravation and an increase of the
frequency of Th17 in the draining lymph nodes of AIA
mice (Fig. 3g).
Together, these data demonstrate that environmental
pollutants with an AHR agonist activity can increase of
Th17 cell development and mediate diseases aggravation.
AHR activation in CD4 T cells induces arthritis
aggravation and is IL-17A-dependent
Similar to what was observed for AIA mice exposed to
cigarette smoke (Fig. 1e), the AHR agonist FICZ failed
to induce arthritis aggravation of AIA in Il17ra−/− mice
(Fig. 4a). Furthermore, the disease-exacerbating effect of
FICZ was also abolished by the treatment with a neutral-
izing anti-IL-17 antibody (Fig. 4b). To investigate
whether the disease-exacerbating effects of AHR activa-
tion on increased articular inflammation was CD4+ T
cell-dependent, we performed AIA in chimeric mice.
Purified WT CD4+ T cells were adoptively transferred
into Ahr−/− mice 1 day before first immunization. Ahr−/−
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mice were not responsive to FICZ in terms of neutrophil
infiltration in the joints, articular hyperalgesia, nor
increase in Th17 cell frequency in the DLNs (Fig. 4c). In
contrast, these responses were completely restored by
the adoptive transfer of CD4+ T cells from WT mice
(Fig. 4c). These results therefore indicate that a direct
activation on CD4+ T cells via Th17 development in vivo
is sufficient for the AHR-dependent aggravation of
articular inflammatory disease.
Discussion
Data presented here demonstrate that cigarette
smoking-induced aggravation of arthritis is dependent
on the activation of AHR and the subsequent induction
of Th17 and production of IL-17A. Our study therefore
provides a hitherto unrecognized direct linear link
among the key players: cigarette smoking and polycyclic
aromatic hydrocarbon, AHR activation, IL-17A produc-
tion, and articular inflammation. The transcriptional
mechanism by which AhR regulates Th17 cell differenti-
ation and expansion is not fully understood. Since forced
expression of AhR did not impact on Rorc expression in
Th17 cells [18] other mechanisms might be involved in
the regulation of Th17 development. Analysis of the Il17
loci revealed a putative binding site for AhR on an E-
box element at the Il17 promoter, suggesting that AhR
might directly regulate IL-17 expression [30]. Moreover,
AHR might also regulate Th17 cell proliferation by the
transcriptional control of miR-132/212 clusters, which
are important for Th17 development [31].
Fig. 1 Cigarette smoke exposure induces arthritis aggravation in an IL-17RA-dependent manner. a AIA mice were exposed to cigarette smoke
during immunization (none, one, two or three cigarettes on days 12 and 17 after immunization). Numbers of neutrophils in the joints and articular
hyperalgesia was determined. b CIA mice were exposed to cigarette smoke (two cigarettes/day) or forced air alone (days 12 and 17 after
immunization). Arthritis incidence and clinical scores were recorded up to day 30 (two-way ANOVA followed by Bonferroni post hoc test; n = 10,
air exposed; n = 10, cigarette smoke). Numbers of neutrophils in the joint was quantified by MPO activity. Mean ± SEM, n = 10, air exposed; n = 9,
cigarette smoke. *P < 0.05, **P < 0.01, ***P < 0.001 (two-sided Student’s t test). c Il17a mRNA expression in DLNs of AIA mice was determined
19 days after the first immunization (as in b). Mean ± SEM, n = 5/group. *P < 0.05, **P < 0.001, one-way ANOVA followed by Bonferroni post hoc
test. d Th17 frequency in DLNs of AIA mice. Mean ± SEM, n = 4/group, *P < 0.05, one-way ANOVA followed by Bonferroni post hoc test. e AIA in
WT or Il17ra−/− mice exposed to cigarette smoke or air (as in b). Mean ± SEM, n = 5/group, ***P < 0.001, one-way-ANOVA followed by Bonferroni
post hoc test. All data are representative of two independent experiments. DLN draining lymph nodes, IL-17 interleukin 17, MPO myeloperoxidase
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In humans, the activation of AhR in Th17 cells might
play a distinct and additive pro-inflammatory role for
RA aggravation (e.g. free radicals induction of oxidative
stress, induction of peptidyl arginine deiminases) [6–12].
Moreover, although other cell types (e.g. ILC3 and γδ T
cells) are also sources of IL-17 during inflammatory
process [32], our data from adoptive transfer experi-
ments suggest that CD4 T cells are the main target
responsible for arthritis aggravation induced by AhR
activation. This is consistent with an earlier report show-
ing that AHR in CD4 T cells, but not in other immune
cells, is important for arthritis development and Th17
expansion [19]. Our study not only corroborates the
previous findings of an AhR cell autonomous role in
CD4 T cells for arthritis development, but identify that
the major environmental risk for RA development,
cigarette smoking, induces disease aggravation through
an AhR-dependent increase in Th17 cell response.
It is worth mentioning that several putative AhR ago-
nists have been described to have immunosuppressive ac-
tivity (e.g. TCDD, Tetrandine, Simomenine) [17, 33–36].
Some of these ligands, including the dioxin 2,3,7,8-Tetra-
chlorodibenzodioxin (TCDD), have been described as
being able to increase Th17 differentiation [37] as well as
Fig. 2 Smoking-induced arthritis aggravation and increase in Th17 activity are AHR-dependent. a Ahr and Cyp1a1 mRNA expression in DLNs from
non-immunized (Naïve), sham-immunized (Sham) and Immunized mice (AIA) 7 days after first immunization. Mean ± SEM, n = 4/group, **P < 0.01
by one-way ANOVA followed by Bonferroni post hoc test. b Cyp1a1 mRNA expression in DLNs of AIA mice 6 h after exposure to cigarette smoke
(two cigarettes, day 12 after immunization). Mean ± SEM, n = 4 mice/group. *P < 0.05, one-way ANOVA followed by Bonferroni post hoc test. c AIA mice
were exposed to cigarette smoke and treated with CH223191. Number of neutrophils in the joints and articular hyperalgesia were determined. Mean
± SEM, n = 4/group, **P < 0.01, ***P < 0.001, one-way ANOVA followed by Bonferroni post hoc est. d Th17 frequency in DLNs of AIA mice exposed to
cigarette smoke and treated with CH22319. Mean ± SEM, n = 4/group, *P < 0.05, one-way ANOVA followed by Bonferroni post hoc test. e Ahr−/− or WT
mice during AIA were exposed to cigarette smoke. Mean ± SEM, n = 4/group. *P < 0.05, **P < 0.01, ***P < 0.001, one-way ANOVA followed by Bonferroni
post hoc test. f Frequency of Th17 cell in the DLNs of WT and Ahr−/− mice exposed to cigarette smoke. Mean ± SEM, n = 4/group. *P < 0.05, **P < 0.01,
one-way ANOVA followed by Bonferroni post hoc test. Data are representative of at least two independent experiments. CH223191
1-Methyl-N-[2-methyl-4-[2-(2-methylphenyl)diazenyl]phenyl-1H-pyrazole-5-carboxamide, DLN draining lymph nodes, IL-17 interleukin 17
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increase the generation of regulatory T cells [17, 37]. In
our experiments, the role of AhR on smoking-induced
arthritis aggravation is demonstrated by the lack of smok-
ing effects on mice genetically deficient to AhR. Moreover,
the AhR antagonist CH223191 also reduced smoking-
induced arthritis aggravation, suggesting blockage of this
receptor could be an important target for RA manage-
ment. The genetic evidence describing that AhR plays a
major role on Th17 differentiation [18, 37], and the AhR-
independent activity of dioxins [38], suggest that some of
the immunosuppressive effects observed could be
dependent of unknown biologic targets of AhR ligands.
In this study, we also identified that PAHs can also
induce arthritis aggravation by modulation of Th17 gen-
eration in vivo and in vitro. It would be of considerable
importance to analyze the active PAHs of cigarette
smoke associated with the exacerbation of RA as several
AHR ligands have been identified in cigarette smoke
[39–41]. Moreover, PAHs and other putative AhR ago-
nists might not only increase AhR activity by direct
binding to this receptor, but also by inhibition of oxi-
dases that degrade the endogenous ligands of AhR [42],
which increase the group of compounds that could affect
the described AhR-Th17 relationship.
Given the promiscuous nature of AHR binding, other
environmental risk factors linked to RA by epidemiologic
evidence are likely to be sources of AHR ligands and could
be related to disease development [21, 41, 43–46]. One
example is the intriguing association of living proximity to
heavy traffic, exposure to traffic pollution, and RA devel-
opment [47]. In our experiments, a brief exposure to
cigarette smoke and AhR activation can induce
Fig. 3 Cigarette smoke and polycyclic aromatic hydrocarbons affect Th17 differentiation and arthritis aggravation. a RLU (relative luminescence
unit) in Hepa1–6.pGL4.43 cells induced by FICZ (300 nM) or cigarette smoke-enriched medium (CSEM: 5, 0.5, 0.05, 0.005 cigarettes/L). Mean ± SEM,
n = 3, *P < 0.05, one-way ANOVA followed by Bonferroni post hoc test. b and c Naive CD4+ T cells from C57BL/6 mice were polarized under Th17
conditions under control medium or CSEM (five cigarettes/L) ± AHR antagonist (CH223191, 30 μM). (d) RLU in Hepa1–6.pGL4.43 cells induced by
FICZ (200 nM) or benzo(b)fluoranthene (BFA: 200, 20, 2 and 0.2 nM). Data are mean ± SEM, n = 3, *P < 0.05 and ***P < 0.001 by one-way ANOVA
followed by Bonferroni post hoc test. e and f Naive CD4+ T cells were polarized under Th17 conditions in the presence of BFA (200 nM),
FICZ (200 nM) or CSEM (five cigarettes/L). Mean ± SEM, n = 3, *P < 0.05, **P < 0.01, one-way ANOVA followed by Bonferroni post hoc test. g
AIA mice were exposed to cigarette smoke (two cigarettes) or treated with BFA (100 μg/kg) or FICZ (90 μg/kg). Number of neutrophils in
the joints, articular hyperalgesia and Th17 cells in DLNs. Mean ± SEM, n = 5/group, *P < 0.05, **P < 0.01, ***P < 0.001, one-way ANOVA
followed by Bonferroni post hoc test. Data are representative of two to three independent experiments. BFA benzo[b]fluoranthen,
CH223191 1-Methyl-N-[2-methyl-4-[2-(2-methylphenyl)diazenyl]phenyl-1H-pyrazole-5-carboxamide, CSEM cigarette smoke-enriched medium,
DLN draining lymph nodes, FICZ 6-formylindolo[3,2-b]carbazole, IL-17 interleukin 17
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aggravation of arthritis, while in humans the timeline for
duration of cigarette smoke exposure and RA develop-
ment might be longer. However, epidemiologic evidence
suggests that even low exposure during the lifetime to
cigarette smoking increases the risk for RA [48]. In
humans, several factors account for the break of self-
tolerance and RA development (e.g. specific microbiota,
genetic background). In our proposed model, cigarette
smoke exposure might potentiate the events that lead to
disease development and aggravation.
Conclusions
This study shows that smoking-induced arthritis aggra-
vation is dependent on AhR activation in Th17 cells and
IL-17Ra signaling. Given the pervasive pathogenic na-
ture of Th17 cells, our findings may also extend to other
diseases such as inflammatory bowel disease [49–51],
atherosclerosis [52, 53], cancer [54, 55] and periodontitis
[56, 57] all of which have a strong link to smoking.
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